METHOD FOR CORRECTION OF CRISIS COURSE OF HYPERTENSIVE DISEASE AND ABDOMINAL OBESITY Russian patent published in 2015 - IPC A61K31/135 A61K31/506 A61P3/04 A61P9/12 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to therapy and endocrinology, and concerns the correction of the crisis course of hypertensive disease and abdominal obesity. To this effect, Moxogamma 200-400 mcg/day and Reduxin 18-30 mg/day are administered with underlying a therapy of the angiotensin converting enzyme inhibitor lisinopril. The preparations are administered in two stages - in the morning and 6 or 7 hours later; Moxogamma is first to be administered, and Reduxin is administered 40-60 min later.

EFFECT: method provides decreasing systolic and diastolic pressure, reducing the signs of cardiac failure and correcting the metabolic disorders by improving the endothelial function, reducing the sympathetic activity and the insulin resistance.

12 tbl, 2 ex